Nyxoah attends Piper Sandler’s 36th Annual Healthcare Conference | 20.11.24

Nyxoah participates in the Piper Sandler 36^e Annual Healthcare Conference

Mont-Saint-Guibert, Belgium – November 20, 2024, 10:05 PM CET / 4:05 PM ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company developing breakthrough treatment alternatives for obstructive sleep apnea (OSA) through neuromodulation, today announced that the Company will participate in the Piper Sandler 36^e Annual Healthcare Conference on Wednesday, December 4, 2024. The company is expected to present via webcast the same day at 2:00 PM ET.

A live audio webcast of the presentation will be available online on the investor relations page of the company’s website at investors.nyxoah.com.

About Nyxoah
Nyxoah reinvents sleep for the billion people suffering from obstructive sleep apnea (OSA). We are a medical technology company developing groundbreaking treatment alternatives for OSA through neuromodulation. Our first innovation is Genio®, a battery-free hypoglossal neuromodulation device that is inserted through a single incision under the chin and controlled by a wearable device. Through our commitment to innovation and clinical evidence, we have demonstrated best-in-class results for reducing the burden of OSA.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and Nasdaq in July 2021. Following positive results from the BETTER SLEEP trial, Nyxoah received CE Mark approval for the expansion of its therapeutic indications to patients with Complete Concentric Collapse (CCC), which are currently contraindicated with competitor therapies. In addition, the company announced positive results from the pivotal DREAM IDE trial for FDA and US commercialization approval.

Caution – CE marked since 2019. Research device in the United States. Restricted by US federal law to research use in the United States.

FORWARD-LOOKING STATEMENTS

Certain statements, beliefs and opinions contained in this press release are forward-looking and reflect Nyxoah’s current expectations and beliefs regarding the Genio® System; planned and ongoing clinical trials of the Genio® System; the potential benefits of the Genio® system; Nyxoah’s objectives regarding the development, regulatory pathway and potential use of the Genio® System; the usefulness of clinical data in potentially obtaining FDA approval for the Genio® System; and possible receipt of FDA approval and entry into the U.S. market. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial consequences of the plans and events described herein. In addition, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of Nyxoah’s Annual Report on Form 20-F for the year ended December 31, 2023 filed with the Securities and Exchange Commission ( “SEC”) on March 20, 2024, and subsequent reports Nyxoah files with the SEC. A variety of factors, including but not limited to changes in demand, competition and technology, could cause actual events, performance or results to differ materially from those anticipated. Forward-looking statements in this press release regarding past trends or activities are not guarantees of future performance and should not be construed as a representation that such trends or activities will continue in the future. Furthermore, even if actual results or developments are consistent with the forward-looking statements in this press release, these results or developments may not be indicative of results or developments in future periods. No representations or warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, Nyxoah expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements contained in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances to which such forward-looking statements relate. similar statements are based on them, unless this is specifically required by law or regulation. Neither Nyxoah, nor its advisors or representatives, nor any of its subsidiaries or the officers or employees of any such person warrant that the assumptions underlying such forward-looking statements will be free from errors nor accept any responsibility for the future accuracy of the forward-looking statements. contained in this press release or the actual occurrence of the predicted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah
John Landry, CFO
[email protected]

For media
In the United States
FINN Partners – Glenn Silver
[email protected]

In Belgium/France
Backstage communication – Gunther De Backer
[email protected]

In International/Germany
MC Services – Anne Hennecke
[email protected]

• DUTCH_NYXH Piper Conf Advisory PR